Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: Management of two cases using fractionated components and factor VIIa

Anesthesia and Analgesia

Volumn 104, Issue 4, 2007, Pages 763-765

  Sniecinski, Roman M ^a   Chen, Edward P ^b   Levy, Jerrold H ^b   Szlam, Fania ^b   Tanaka, Kenichi A ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 7A; HEPARIN; KALLIKREIN INHIBITOR; KAOLIN; PROTAMINE; SERUM ALBUMIN;

ADULT; ANESTHESIST; AORTA ANEURYSM; AORTA ROOT; AORTA SURGERY; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BLOOD CONSERVATION; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CASE REPORT; CORONARY ARTERY RECANALIZATION; CRYOPRECIPITATE; FIBRINOGEN BLOOD LEVEL; FRACTIONATION; HEMATOCRIT; HEMODILUTION; HEMOSTASIS; HUMAN; INTENSIVE CARE UNIT; INTERVIEW; JEHOVAH'S WITNESS; MARFAN SYNDROME; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STERNOTOMY; THROMBOCYTE COUNT; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ADULT; ANTICOAGULANTS; ANTITHROMBINS; AORTIC ANEURYSM; BLOOD LOSS, SURGICAL; CARDIOPULMONARY BYPASS; COAGULANTS; FACTOR VIIA; FACTOR VIII; FIBRINOGEN; HUMANS; INFORMED CONSENT; JEHOVAH'S WITNESSES; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PHYSICIAN-PATIENT RELATIONS; RECOMBINANT PROTEINS; RELIGION AND MEDICINE; UNITED STATES;

EID: 34047259331     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000250913.45299.f3     Document Type: Article

References (13)

1. Despotis GJ, Filos KS, Zoys TN, et al. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996;82:13-21.
2. Moskowitz DM, Perelman SI, Cousineau KM, et al. Multidisciplinary management of a Jehovah's Witness patient for the removal of a renal cell carcinoma extending into the right atrium. Can J Anaesth 2002;49:402-8.
3. Beholz S, Liu R, Thoelke R, et al. Use of desmopressin and erythropoietin in an anaemic Jehovah's Witness patient with severely impaired coagulation capacity undergoing stentless aortic valve replacement. Perfusion 2001;16:485-9.
4. Tanaka KA, Waly AA, Cooper WA, Levy JH. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven). Anesthesiology 2003;98:1513-15.
5. Watch Tower Bible and Tract Society. questions from readers. Watchtower 2000;June 15:29-31.
6. Muramoto O. Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's Witnesses. BMJ 2001;322:37-9.
7. Greilich PE, Brouse CF, Beckman J, et al. Reductions in platelet contractile force correlate with duration of cardiopulmonary bypass and blood loss in patients undergoing cardiac surgery. Thromb Res 2002;105:523-9.
8. Hunt BJ, Parrat RN, Segal HC, et al. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg 1998;65:712-18.
9. Lisman T, Adelmeijer J, Cauwenberghs S, et al. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005;3:742-51.
10. Hedner U. Dosing with recombinant factor VIIa based on current evidence. Semin Hematol 2004;41:35-9.
11. DiDomenico RJ, Massad MG, Kpodonu J, et al. Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass. Chest 2005;127:1828-35.
12. Avidan MS, Levy JH, Scholz J, et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005;102:276-84.
13. Heindel SW, Mill MR, Freid EB, et al. Fatal thrombosis associated with a hemi-fontan procedure, heparin-protamine reversal, and aprotinin. Anesthesiology 2001;94:369-71.